AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01542788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SOF
Description: Placebo to match SOF was administered orally once daily.
Study NCT01542788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match RBV
Description: Placebo to match RBV was administered orally twice daily.
Study NCT01657357 — intervention group
Intervention type: OTHER
Intervention: Routine followup
Description: questionnaires
Study NCT06443814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
Study NCT06443814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
Study NCT04526665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80mg
Description: Elafibranor 80mg daily
Study NCT04526665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study NCT03601897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally
Study NCT03000309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Study NCT03601897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2
Study NCT01088906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
Study NCT00208338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTORE SIS Patch
Description: Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
Study NCT00208338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Standard surgical repair of torn rotator cuff
Study NCT01821755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foster parent intervention
Description: parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
Study NCT03370315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Program
Description: The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
Study NCT03370315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
Study NCT02449187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310, Fasted followed by fed
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.
Study NCT02449187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310, Fed followed by fasted
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
Study NCT04079712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01030536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 30 mcg/kg
Description: Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study NCT01030536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 40 mcg/kg
Description: Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study NCT04079712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04079712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05231018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: 8-sessions psychotherapy
Study NCT00218036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Description: 10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
Study NCT00218036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Description: 10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
Study NCT01563341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
Study NCT03370276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
Study NCT01030536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 50 mcg/kg
Description: Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study NCT01030536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 60 mcg/kg
Description: Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study NCT00218036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: 10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
Study NCT03370276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
Study NCT02153957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12 weeks of enhanced physical activity with Zamzee monitor.
Study NCT02153957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: 12 weeks of enhanced physical activity with Zamzee monitor.
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study NCT00218036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 40mg
Description: 10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
Study NCT00218036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
Study NCT02844023 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical evaluation
Description: With questionnaire.
Study NCT02844023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paraclinical evaluation
Description: Symptom inflammatory, biomarkers.
Study NCT02844023 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging
Description: Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
Study NCT02844023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmologic examination
Study NCT02844023 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dosage of biomarkers
Description: Control patients.
Study NCT03273738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: folate level measurement
Description: the level of folate measured in plasma with homocysteine
Study NCT03273738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: B12
Description: B12 measurement in blood
Study NCT01966562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHOLE-BODY VIBRATION TRAINING
Description: The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
Study NCT01966562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MULTICOMPONENT TRAINING
Description: This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT01452958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF-alpha
Description: Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
Study NCT01452958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Study protocol 2:0,075 ng/kg/h intravenous
Study NCT02929563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study NCT01841736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01841736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02929563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for pantoprazole)
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT01841736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01841736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT01841736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01841736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study NCT01841736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study NCT04352322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A+HA(tm)
Description: oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
Study NCT04352322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution with no active ingredients
Study NCT01014637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amorolfine (Antifungal)
Description: Treatment with Amorolfine for 36 weeks
Study NCT01014637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
Description: Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
Study NCT01957826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow-derived MSCs injection
Description: transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
Study NCT01957826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: placebo administration
Study NCT02800564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active mass media approach
Description: Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
Study NCT04227587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
Study NCT02261896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Evaluate usefullness of antibiotic prophylaxis
Study NCT02800564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive mass media approach
Description: These communities will be exposed to twice weekly radio programming for up to 18 months only.
Study NCT04227587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: We offer a 2-session education course to teach the subjects about sleep hygiene practice.
Study NCT01714674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary nitrate beverage
Description: ingestion of single dose NaNO3 beverage two hours prior to exercise bout
Study NCT01714674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl beverage
Description: ingestion of single dose NaCl beverage two hours prior to exercise bout
Study NCT02261896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
Study NCT01823055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal suture capturing mesh device
Description: The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
Study NCT00137592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: small media, group education (multicomponent)
Study NCT00621283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study NCT01029002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
Study NCT01029002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to this arm will receive one placebo pill once weekly.
Study NCT00775658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine
Description: olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
Study NCT01931462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave pre-coagulation
Description: The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
Study NCT00837512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Microneedle used to deliver insulin at a depth less than 900 micrometers
Study NCT00775658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Study NCT01352962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000mg/m2 IVPB over 30 min x 1
Study NCT01352962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5\*\* IVPB over 30 min x 1
Study NCT01352962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
Study NCT03687528 — intervention group
Intervention type: RADIATION
Intervention: CT-scanner
Description: After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
Study NCT04128566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking stress test
Description: walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
Study NCT03650764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
Study NCT00837512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin catheter
Description: Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
Study NCT00369668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral movements and neuromuscular electrical stimulation
Description: Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.